

ACT Accelerator (ACT-A) and COVAX

Vx safety ecosystem workshop

9 September 2020

RECAP:

ACT-A's goal is to reduce COVID mortality & severe disease through accelerated development, equitable allocation & scaled up delivery of...

Vaccines



**2 billion
doses** by the
end of 2021

Therapeutics



**245 million
courses** by
mid-2021


Diagnostics



**500 million
tests** by mid-
2021

...thereby protecting health systems & restoring societies & economies

RECAP: The ACT Accelerator



- **3 vertical Pillars** are the **primary drivers** of ACT's product work
- A cross-cutting **Access & Allocation Workstream** delivers equity
- **A Health Systems Connector** drives optimal utilization
- **Support mechanisms** incl. 2 Special Envoys & ACT Support Hub

RECAP: The ACT Timeline

Phase 1:

- Expand existing diagnostics & identify viable new tools

Phase 2:

- Introduce new tools to supplement current approach

Phase 3:

- Transition to new tools as primary intervention

2020

Q2

Q3

Q4

2021

Q1

Q2

Q3

Q4

Initiate production on promising new products

Simultaneous rollout in priority populations

Full scale production and delivery for mass coverage

Work across the 4 Pillars will be adapted to the evolving epidemiology, trial results, and tools

The case for ACT is even stronger

Vaccines, therapeutics & diagnostics are essential to global recovery

Lockdowns are not a solution

- Unsustainable in HICs / UMICs & unimplementable in LMICs

All populations are still at risk


- Serology data reveal massive immunity gaps everywhere

Countries can't beat COVID alone

- Interconnectivity undermines every country's emergence from lockdown


COVID is not coming under control


— COVID-19 response stringency¹ (global mean index points)
— New COVID-19 cases / day (000'), global



1. Based on University of Oxford's Coronavirus Government Response Tracker, "Stringency" measures the strictness of 'lockdown style' NPI policies that primarily restrict behavior
SOURCE: Oxford COVID-19 Government Response Tracker; WHO

ACT is successfully harnessing the international health ecosystem

 Co-conveners



Key success factors: deep engagement of Principals, integrated workplans & budgets, leveraging the best of each agency

ACT already has an impressive track record

Vaccines



- **9 vaccine candidates** already in portfolio
 - **Broadest portfolio** across geographies & tech platforms
 - **COVAX Vaccines Facility** launched (>170 countries, 70% global pop)
-

Therapeutics



- **1st new treatment secured** for LMICs (Dexamethasone)
 - Key novel **drugs under evaluation**
-

Diagnostics




- **50+ test kits** under evaluation
 - **10+ million kits** procured (with Dx consortium)
 - Promising **rapid Antigen diagnostic test(s)** identified
-

Allocation



- **Equitable Access Principles** agreed
- **Draft Allocation Framework** issued for consultation

Overview of COVAX setup – agreed organization¹




3 workstreams Multiple sub-workstreams & SWAT teams

Cross-cutting topics

1. Not representing the structure but the organization of working teams/sub-teams within COVAX

Three components informing countries to formulate the in-country vaccination strategy




BACK-UP

Challenges heading into the next phase of ACT-A

At 24 August


Insufficient financing

US\$ B rounded (Vaccines, Tx, Diagnostics only)



Inefficient vaccine distribution

Vaccine doses secured¹, M doses by 2021



1. Based on publicly disclosed agreements

2. Cumulative numbers

3. European Commission Inclusive Vaccines Alliance

SOURCE: IMF Estimates; Press releases; OECD; WHO; World Bank; The Economist Intelligence Unit